Arvinas reported revenues of $32.5 million and a net loss of $81.9 million for the quarter ended March 31, 2023. The company's cash, cash equivalents, restricted cash and marketable securities were $1,129.0 million as of March 31, 2023, which is expected to fund operations into 2026.
Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies
Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests potential clinical benefit in a heavily pretreated patient population
The safety lead-in is on-track to initiate in 2H 2023 to evaluate the best starting dose of palbociclib (100 mg or 75 mg) in combination with vepdegestrant 200 mg once daily
Initiate a global Phase 3 trial with bavdegalutamide in mCRPC for patients with AR T878/H875 tumor mutations (2H 2023).
Arvinas believes its cash, cash equivalents, restricted cash and marketable securities as of March 31, 2023, is sufficient to fund planned operating expenses and capital expenditure requirements into 2026.
Analyze how earnings announcements historically affect stock price performance